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Members of the vascular endothelial growth factor (VEGF) family differently regulate processes in retinal
endothelial cells (REC) which are crucially involved in the pathogenesis of diabetic retinopathy: Both,
VEGF-A and placenta growth factor (PlGF), stimulate proliferation of primary and immortalized bovine
REC ((i)BREC) but only VEGF-A165 stimulates their migration. Diabetic macular edema is most likely a
consequence of an elevated permeability of REC which can be induced by VEGF-A, but not by PlGF.
Binding of VEGF-A by the antibody fragment ranibizumab is sufﬁcient to completely restore or prevent
VEGF-A-induced disturbance of the iBREC barrier or migration of these cells without affecting the basal
processes. This was observed even in the presence of other growth factors when surplus proliferation
was only partly blocked. The recombinant protein aﬂibercept (VEGF-trap) not only binds very strongly to
VEGF-A, but e in contrast to ranibizumab e also recognizes PlGF. In this study, we investigated whether
this additional targeting of PlGF also results in better inhibition of growth factor-induced proliferation
and migration, and disturbance of the iBREC barrier. In addition, uptake of aﬂibercept by iBREC and
potential functional consequences were examined. In accordance with its binding speciﬁcity, aﬂibercept
strongly and speciﬁcally inhibited iBREC proliferation stimulated with VEGF-A, PlGF or a combination of
these factors. By treatment with aﬂibercept at therapeutically achievable concentrations, VEGF-A-
stimulated iBREC migration was reduced not only to normal values but driven below the basal level.
However, the VEGF-A binding humanized antibody bevacizumab as well as the unrelated control anti-
body rituximab also inhibited basal or VEGF-A stimulated migration at clinically relevant concentrations,
suggesting an effect of high amounts of IgG domain-containing proteins which does not depend on their
binding speciﬁcity. However, aﬂibercept speciﬁcally blocked VEGF-A stimulated migration at lower
concentration without inﬂuencing basal processes. Effects on permeability were determined by
measuring transendothelial resistance (TER) of iBREC (VEGF-A165) and their expression of the tight
junction protein claudin-1. The VEGF-A-disturbed barrier was completely restored by treatment with
25 mg/ml aﬂibercept of which even much higher concentrations did not interfere with normal barrier
function. Uptake of aﬂibercept by iBREC e analyzed by Western blot e was observed after 1 h of
treatment and the amount further increased during prolonged incubation. Most of the internalized
aﬂibercept was present in subcellular fractions of proteins assigned to the membranes and organelles,
but it was also detected in the fraction consisting of cytoskeletal proteins. Co-immunoﬂuorescence
staining showed aﬂibercept absorbed by iBREC to be localized in or close to the Golgi apparatus. Aﬂi-
bercept at high concentrations interferes with an important normal iBREC function, but prevents and
restores VEGF-A-induced disturbances at considerably lower concentrations. Therefore, reduction of the
doses administered in DR and DME therapy might be considered.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).ax: þ49 731 500 59192.
(H.L. Deissler).
Ltd. This is an open access article u1. Introduction
The pathogenesis of diabetic retinopathy (DR), which is still a
leading cause of blindness in developed countries, is associated
with deregulated expression of various cytokines. Of these,
vascular endothelial growth factor A (VEGF-A) is considered very
important because its levels were found to be elevated in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Abbreviations
AIF apoptosis inducing factor
bFGF basic ﬁbroblast growth factor
(i)BREC (immortalized) bovine retinal endothelial cells
DME diabetic macular edema
DR diabetic retinopathy
EC endothelial cells;
ECGM endothelial cell growth medium
ECGS/H endothelial cell growth supplement/H
FcRn neonatal Fc receptor
FCS fetal calf serum
HUVEC endothelial cells of the human umbilical cord
MAb monoclonal antibody
PBSd phosphate buffered saline without Ca2þ- and Mg2þ-
ions
PDI protein disulﬁde isomerase
PlGF placental growth factor
REC retinal endothelial cells
SFM serum-free medium
SRM serum-reduced medium
TER transendothelial resistance
TJ tight junction
TRT telomerase reverse transcriptase
VECad vascular endothelial cadherin
VEGF-A vascular endothelial growth factor A
VEGFR1 VEGF receptor 1
VEGFR2 VEGF receptor 2
vWF von Willebrand factor
ZO-1 zona occludens-1
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et al., 1994). Concentrations of other members of the VEGF pro-
tein family like placental growth factor (PlGF) are increased in the
vitreous humor only when the disease has progressed to the
proliferative stage (Khaliq et al., 1998). Proliferation of primary or
immortalized endothelial cells of the bovine retina ((i)BREC) is
indeed stimulated by isoforms VEGF-A165 and VEGF-A121 as well
as by PlGF-1 and PlGF-2, but only VEGF-A165 also initiates
migration (Castellon et al., 2002; Deissler et al., 2005, 2008,
2013a). Sight-threatening diabetic macular edema (DME) that
may appear at any stage of DR, is also most likely caused by
VEGF-A-induced elevated permeability of retinal endothelial cells
(REC) (Nguyen et al., 2006; Qaum et al., 2001). Exposure to VEGF-
A165 but not to PlGF results in strongly elevated permeability of
primary or immortalized BREC, whereas VEGF-A121 has a much
weaker effect (Cai et al., 2011; Deissler et al., 2013b). Higher
permeability of (retinal) endothelial cell (EC) layers is typically
associated with altered intracellular localization, expression and/
or modiﬁcation of tight junction (TJ) proteins (Bazzoni, 2006; Cai
et al., 2011; Deissler et al., 2008, 2010, 2011; Harhaj et al., 2006;
Wisniewska-Kruk et al., 2012). Particularly the TJ protein
claudin-1 was found down-regulated and delocalized from the
plasma membrane when damaging effects of VEGF-A165 on REC
barrier function were studied in vitro over several days, whereas
only subtle changes of other TJ-proteins were observed (Deissler
et al., 2008, 2010, 2011).
Several proteins that speciﬁcally bind to VEGF-A have been
developed as therapeutic agents (Presta et al., 1997; Holash et al.,
2002; Ferrara et al., 2006) and their VEGF-depleting activities
have been conﬁrmed in vitro: Complete reversion of the iBREC
barrier disruption induced by VEGF-A165 can be achieved by
treatment with the VEGF-A binding antibody fragment ranibizu-
mab (Ferrara et al., 2006) even in the presence of other growth
factors, e.g. PlGF (Deissler et al., 2011, 2013b). Likewise, ranibizu-
mab completely prevents stimulation of iBREC migration with
VEGF-A165 as single agent or together with other growth factors
(Deissler et al., 2008, 2013a). In accordance with its binding
speciﬁcity, ranibizumab also completely inhibits VEGF-A-
stimulated proliferation of human or bovine REC (Deissler et al.,
2008; Stewart et al., 2011) but fails to do so when PlGF is pre-
sent (Deissler et al., 2013a). The recombinant protein aﬂibercept
(VEGF-trap) consists of the VEGF binding domain 2 of VEGF re-
ceptor 1 (VEGFR1), the binding domain 3 of VEGFR2 and an IgG-Fc
part (Holash et al., 2002). Reﬂecting the speciﬁcities of its receptor
domains, aﬂibercept can bind PlGF in addition to VEGF-A(Papadopoulos et al., 2012). Accordingly, aﬂibercept efﬁciently
prevents VEGF-A-induced BREC proliferation (Yu et al., 2011) and
migration of endothelial cells of the human umbilical cord
(HUVEC) stimulated by PlGF (Papadopoulos et al., 2012). Very
similar to the effects of ranibizumab, the humanized VEGF-A
binding antibody bevacizumab (Presta et al., 1997) prevents and
reverses disturbances caused by VEGF-A in iBREC and human REC
but it is slightly less efﬁcient (Stewart et al., 2011; Deissler et al.,
2012). Therefore bevacizumab is also used for DME therapy
although only ranibizumab and aﬂibercept have been approved by
regulatory agencies (Arevalo et al., 2011; Mitchell et al., 2011; Do
et al., 2012).
Although ranibizumab and bevacizumab inhibit or prevent
VEGF-induced processes similarly by removing the growth factor,
their properties differ in some details: Only bevacizumab is inter-
nalized by retinal pigment epithelial cells which is associated with
inhibition of phagocytosis and an elevated permeability (Klettner
et al., 2009, 2010; Miura et al., 2010). Bevacizumab is also inter-
nalized by iBREC in which it unspeciﬁcally inhibits their migration.
This effect was not observed in similar experiments with ranibi-
zumab (Deissler et al., 2012).
Based on the in vitro studies to characterize the previously
established VEGF-depleting drugs, we studied the effects of aﬂi-
bercept on VEGF-A-induced proliferation, migration and barrier
disturbance of iBREC. In addition, we investigated the internaliza-
tion of aﬂibercept by this cell type and whether vital cellular
functions are altered as a consequence.
2. Materials and methods
2.1. Reagents, antibodies and media
Recombinant human growth factors rhVEGF-A165 (SF21-
expressed), rh basic ﬁbroblast growth factor (bFGF) and rhPlGF-
1 (both E. coli-expressed) were purchased from R&D Systems
(Wiesbaden, Germany); torhVEGF-A121 (SF21-expressed) from
Calbiochem (Merck, Darmstadt, Germany), and rhPlGF-2 (E. coli-
expressed) from PeproTech (Hamburg, Germany). Rabbit poly-
clonal antibodies binding to human claudin-1 (JAY.8), ZO-1 (Z-R1)
or claudin-5 (Z43.JK), a mouse monoclonal antibody (MAb)
directed against human golgin-97 (clone CDF4) as well as detec-
tion antibodies (F(ab’)2 conjugated with AlexaFluor 594 or Alex-
aFluor 488) were from Life Technologies (Karlsruhe, Germany).
Horseradish peroxidase-conjugated detection antibodies directed
against rabbit or mouse IgG were from BioRad (Munich,
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Rabbit polyclonal antibodies binding to human and bovine VE-
cadherin (VECad) and a mouse MAb against CD63 were pur-
chased from Acris (Herford, Germany). Rabbit polyclonal anti-
bodies used to detect von Willebrand Factor (vWF) were from
Dako GmbH (Hamburg, Germany), a mouse MAb detecting actin
and mouse MAb 58K-9 binding to a protein associated with the
Golgi apparatus (Gao and Sztul, 1999) from Abcam (Cambridge,
UK). Rabbit MAbs detecting apoptosis inducing factor (AIF) or
protein disulﬁde isomerase (PDI) were purchased from Cell
Signaling Technology/New England Biolabs GmbH (Frankfurt,
Germany). The Fab fragment ranibizumab (Lucentis; 10 mg/ml in
10 mM histidine-HCl, 10% a,a-trehalose dihydrate, 0.01% poly-
sorbate 20, pH 5.5; Ferrara et al., 2006) of a humanized VEGF-
binding antibody was a gift from Novartis Pharma GmbH (Nur-
emberg, Germany). Eylea (40 mg/ml aﬂibercept in 10 mM sodium
phosphate, 40 mM NaCl, 0.03% polysorbate 20, 5% sucrose, pH 6.2;
Do et al., 2012) was purchased from Bayer Pharma (Berlin, Ger-
many) and Zaltrap (25 mg/ml aﬂibercept in 5 mM sodium phos-
phate, 100 mM NaCl, 5 mM Na-citrate, 0.1% polysorbate 20, 20%
sucrose, pH 6.2) from Sanoﬁ-Aventis (Bridgewater NJ, USA). The
humanized anti-VEGF antibody bevacizumab (Avastin; 25 mg/ml
in 50 mM sodium phosphate, 6% a,a-trehalose dihydrate, 0.04%
polysorbate 20, pH 6.2; Presta et al., 1997) was repackaged at the
pharmacy of the University Hospital Ulm and provided in syringes
which were stored at 4 C. In the laboratory, the antibody was
stored for less than 2 weeks in inert plastic vials. The CD20-
speciﬁc humanized monoclonal antibody rituximab (MabThera;
10 mg/ml in 25 mM sodium citrate, 155 mM NaCl, 0.07% poly-
sorbate 80, pH 6.5; Reff et al., 1994) was purchased from Roche
Pharma (Basel, Switzerland) and aliquot parts were stored in inert
plastic vials at 4 C.
2.2. Cultivation of iBREC
Telomerase-immortalized microvascular endothelial cells from
bovine retina (iBREC) have been established and characterized in
our laboratory (Deissler et al., 2005). Immortalizing primary cells
by ectopic expression of human telomerase reverse transcriptase
(TRT) is usually not associated with signiﬁcant changes in impor-
tant cellular processes and the amount of human TRT measured in
iBREC is similar to that of the bovine homologue expressed by
shortly cultivated primary BREC. Typical expression of von Wille-
brand factor, VECad, TJ-proteins claudin-1, claudin-3, claudin-5, ZO-
1 and occludin, as well as VEGF receptors VEGFR1, VEGFR2 and
neuropilin-1 was conﬁrmed every few weeks during cultivation of
the cells (Deissler et al., 2005, 2008, 2010, 2011). Although of bovine
origin, iBREC can be stimulated with human recombinant growth
factors (Deissler et al., 2005, 2008, 2010, 2011, 2013a). Reproducible
responses to growth factors were also considered indicative of a
stable and authentic cell system.
iBREC were cultivated in Endothelial Cell Growth Medium MV
(ECGM-hHC; Promocell, Heidelberg, Germany) containing 0.4%
Endothelial Cell Growth Supplement/H (ECGS/H, 90 mg/ml
heparin), 10 ng/ml epidermal growth factor, 2.8 mM hydrocortisone
and 5% fetal calf serum (FCS) on ﬁbronectin-coated (50 mg/ml; BD
Biosciences, Heidelberg, Germany) surfaces as previously described
(Deissler et al., 2005, 2011). Cells were used in the experiments at
passages 20e35 counting from the stage of primary culture, for
which stable expression of investigated proteins had been
conﬁrmed. After cultivation for 3 days the conﬂuent iBREC mono-
layer had formed a tight barrier indicated by a stable trans-
endothelial resistance of 50 Ohm  cm2 which is in accordance
with values reported for monolayers of primary BREC (Deissler
et al., 2011; Tretiach et al., 2003).2.3. Cell proliferation assay
In a 96-well plate, 5  103 iBREC in ECGM-nHC (like ECGM-hHC
but with 103 nM hydrocortisone) were allowed to attach to the
ﬁbronectin-coated bottom of a cavity overnight. The medium was
then changed to serum-free medium (SFM; containing 0.4% ECGS/
H, 1 mg/ml ﬁbronectin and 103 nM hydrocortisone). After cultiva-
tion for 24 h, cells were exposed for 48 h to growth factors VEGF-
A165, VEGF-A121, PlGF-1, PlGF-2 or bFGF, each applied at 10 ng/ml as
single agents or in combination, and 250 mg/ml aﬂibercept (Eylea)
in SFM. Enzymatic conversion of WST-1 (Roche Diagnostics, Man-
nheim, Germany), indicative of proliferating cells, was then
measured according to the manufacturer’s protocol in 16 replicate
wells (Deissler et al., 2008). Values were normalized in relation to
those obtained with control cells not treated with effectors. Results
were shown only of experiments in which iBREC were treated with
growth factors for 48 h because different effects were not observed
during shorter or prolonged exposure.2.4. Cell migration assay
Transmembrane cell migration assays were performed in a
modiﬁed Boyden chamber consisting of 12-well cell culture plates
and inserts with a porous membrane (pore size 8.0 mm, B 1 cm; BD
Biosciences). Their lower compartments were ﬁlled with SFM
(without ECGS/H but containing 5 mg/ml ﬁbronectin) which was
supplemented with 1.5e150 mg/ml aﬂibercept or rituximab. Inser-
ted membranes were initially incubated for 1 h at 37 C before
400 ml SFM (without ECGS/H and ﬁbronectin) and a suspension of
105 iBREC in 100 ml of this mediumwere added subsequently to the
upper compartment. After 20 h at 37 C, migration of cells through
the pores of the membrane was assessed as described (Deissler
et al., 2008). Cells remaining on top of the membrane were scra-
ped off and cells which had migrated to the lower surface of the
membrane were ﬁxed in methanol at 20 C for 15 min. Nuclei of
migrated cells were stained by mounting the membrane in
VectaShield-DAPI (Vector Laboratories, Axxora, Grünberg, Ger-
many) and visualized by ﬂuorescence microscopy (DM4000B
ﬂuorescence microscope; Leica, Wetzlar, Germany). Cells were
counted in triplicate wells in 4 randomly chosen microscopic ﬁelds.
Values were normalized in relation to those obtained with control
cells not treated with effectors. To investigate speciﬁc inhibition of
VEGF-induced migration, 25 ng/ml VEGF-A165 together with 1.5e
150 mg/ml aﬂibercept or with 15 and 150 mg/ml rituximab was
added to the lower compartment. iBREC migration towards 150 mg/
ml aﬂibercept together with a mixture of VEGF-A165, VEGF-A121,
PlGF-1, and PlGF-2 (each at a ﬁnal concentration of 25 ng/ml) was
also measured.2.5. Wound healing assays
Wound healing assays to measure horizontal migration of cells
into a gap in the monolayer were performed as previously
described (Deissler et al., 2007): iBREC were grown to conﬂuence
on ﬁbronectin-coated two-chamber slides (Nunc, Wiesbaden,
Germany) in ECGM-nHC. The cell monolayer was disrupted with a
cell scraper (2 mm), cells were washed with phosphate buffered
saline without Ca2þ/Mg2þ (PBSd) and ECGM-nHC (supplemented
with 1 mg/ml ﬁbronectin) with or without 250 mg/ml aﬂibercept
(Eylea) or rituximab was added. The gap size was measured at
different time points up to 3 d after setting the lesion in 8 randomly
chosen microscopic ﬁelds in at least 6 slides per tested variation.
Normalized values were calculated in relation to those measured
30 min after setting the lesion.
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To study the effects of VEGF inhibitors or of the unrelated con-
trol antibody on non-stimulated iBREC, cells were kept in ECGM-
nHC with bevacizumab, aﬂibercept or rituximab (all at 250 mg/ml)
for periods from 1 h to 6 d without changing the medium. Similar
experiments were performed with iBREC also cultured in SFM
(without ﬁbronectin) to investigate the effect of ﬁbronectin on
uptake of aﬂibercept. Then cell extracts were prepared and
analyzed essentially as described (Deissler et al., 2012). Subcellular
fractions, i.e. proteins localized in the cytoplasm, in membranes/
organelles, and components of the cytoskeleton, were prepared
with the ProteoExtract Subcellular Proteome Extraction Kit (Merck,
Darmstadt, Germany) according to the manufacturer’s instructions
as described previously (Deissler et al., 2012).
Experiments with conﬂuent iBREC to investigate the potential of
VEGF-binding proteins to restore barrier function were initiated by
replacing ECGM-nHC with serum-reduced medium (SRM; con-
taining 0.4% ECGS/H, 0.25% FCS, 1 mg/ml ﬁbronectin and 103 nM
hydrocortisone) for 24 h. After treatment with 100 ng/ml VEGF-
A165 for 30 h, mediumwas exchanged with SRM containing 100 ng/
ml VEGF-A165 together with 0.01e100 mg/ml ranibizumab (w0.2e
2000 nM), 0.025e250 mg/ml aﬂibercept (w0.2e2000 nM), 250 mg/
ml bevacizumab, or rituximab (w2 mM) before cell extracts were
prepared 24 h later (Deissler et al., 2011).
2.7. Western blot analyses
Western blot analyses of whole cell extracts or subcellular
fractions were performed as described: Proteins were separated by
electrophoresis in a 4e20% SDS-polyacrylamide gradient gel (Bio-
Rad, Munich, Germany) under reducing conditions and transferred
by electroblotting in transfer buffer (192 mM glycine, 25 mM Tris,
pH8.4) to a polyvinylidene diﬂuoride membrane (BioRad) (Deissler
et al., 2011) Antigen-bound primary antibodies were detected using
appropriate IgG horseradish peroxidase conjugates (1:7500 in
PBSd, 0.1% Tween-20; BioRad) and the ECL-chemiluminescence kit
(Thermo Scientiﬁc, Bonn, Germany) according to the supplier’s
protocol. To verify loading of equal amounts of protein, expression
of actin was assessed in parallel using mouse monoclonal antibody
AC-40 (Abcam, Cambrigde, UK). Analyses including speciﬁc detec-
tion of aﬂibercept, rituximab, bevacizumab or ranibizumab were
based on immunoreactivity of polyclonal antibodies (coupled to
horseradish peroxidase, diluted 1:20,000) with human IgG. For
their semi-quantitative assessment, speciﬁc chemiluminescence
signals were compared with those of standard samples of which
0.5 nge5 ng were loaded. Under these conditions, aﬂibercept gave
rise to a diffuse band at<70 kDawhich is due to glycosylation of the
protein. Antibodies bevacizumab and rituximab showed two bands
atw55 kDa and 25 kDa corresponding to the heavy or light chains
of the IgGs, respectively. A speciﬁc band atw25 kDa was observed
for the Fab-fragment ranibizumab.
2.8. Transendothelial electrical resistance of cell layers
To assess paracellular permeability of iBREC, transendothelial
electrical resistance (TER) was measured essentially as described
(Deissler et al., 2010, 2011). Normalized TER values were calculated
in relation to the TER measured in medium immediately before the
medium was replaced by fresh medium containing effectors.
2.9. Immunoﬂuorescence staining
Conﬂuent monolayers of iBREC on ﬁbronectin-coated two-
chamber slides were treated with effectors as described above andrelevant proteins were visualized by immunoﬂuorescence staining
(Deissler et al., 2008, 2012). Internalized aﬂibercept, bevacizumab
and rituximab were detected by incubation with AlexaFluor 594-
coupled polyclonal antibodies (1:10,000) against human IgG for
90 min after blocking with 10% FCS/PBSd for 30 min. For double-
immunoﬂuorescence staining, slides were then incubated with
antibodies against CD63, AIF, PDI, vWF, golgin-97 or with MAb 58K-
9 Golgi (all diluted in PBSd) for 90 min. AlexaFluor 488-conjugated
(F(ab’)2) fragments were used to detect bound rabbit or mouse
primary antibodies. Eventually, the chamber slides were washed
and the cells embedded in VectaShield-Dapi, before they were
examined by ﬂuorescence microscopy. To determine the limit of
detection, diluted samples of aﬂibercept or rituximab were applied
to an appropriate membrane and processed alike.
2.10. General considerations and statistical analyses
In all experiments, control cells were processed identically in
medium only lacking the effector(s) under investigation. All ex-
periments were repeated at least three times and in each experi-
ment data were generated from multiple replicates. The Manne
Whitney U test was used to compare sets of experimental data and
differences resulting in p-values below 0.05 were considered sig-
niﬁcant. Results were presented either as conventional boxe
whiskers diagrams showingmeans and percentiles (75%, 25%) or by
providing means and corresponding standard deviations.
3. Results
3.1. General remarks
Effects of different growth factors and the VEGF-binding pro-
teins on iBREC functions were studied under experimental condi-
tions which were deﬁned by important previous observations: The
concentrations of growth factors (10e25 ng/ml) were found to be
sufﬁcient for speciﬁc and strong stimulation of proliferation or
migration of ((i)B)REC (Castellon et al., 2002; Deissler et al., 2005,
2008; Stewart et al., 2011). Speciﬁc inhibition of VEGF-induced
iBREC proliferation or migration without affecting basal processes
was observed with (therapeutically achievable) 100 or 60 mg/ml
ranibizumab, respectively (Deissler et al., 2008; Mitchell et al.,
2011). To stably disturb the barrier function of (i)BREC a concen-
tration of 25 ng/ml VEGF-A165 is sufﬁcient and necessary, and
normalization can be achieved with (therapeutically achievable)
100 mg/ml ranibizumab or 250 mg/ml bevacizumab (Harhaj et al.,
2006; Deissler et al., 2011, 2012). In order to detect putative side
effects of aﬂibercept, the VEGF-binding protein was used in most
experiments at a clinically relevant concentration of 250 mg/ml.
3.2. Aﬂibercept inhibits VEGF-induced proliferation
Previous studies showed that 10 ng/ml VEGF-A165, VEGF-A121,
PlGF-1 or PlGF-2 were sufﬁcient for speciﬁc and strong stimulation
of iBREC proliferation (Deissler et al., 2008, 2013a). In accordance
with its binding speciﬁcity, ranibizumab at clinically relevant
100 mg/ml completely inhibited proliferation induced by VEGF-A,
but failed to do so when proliferation was stimulated by PlGF or
this factor in combination with VEGF-A (Deissler et al., 2008,
2013a). Because aﬂibercept additionally binds PlGF, we investi-
gated the potentially better inhibition of co-stimulated prolifera-
tion. Serum-starved iBREC were exposed to 10 ng/ml VEGF-A and/
or PlGF and (therapeutically achievable) 250 mg/ml aﬂibercept for
2 d, before conversion of WST-1 was determined as a measure of
cell proliferation. Zaltrap inhibited basal proliferation (normalized
values of 1.00  0.27 for control and 0.83  0.16 for 250 mg/ml
Table 1
Proliferation of iBREC stimulated by VEGF-A and/or PlGF was completely inhibited by aﬂibercept. Serum-starved iBREC were stimulated with growth factors (10 ng/ml each)
and incubated with or without 250 mg/ml aﬂibercept (Eylea) for 48 h, before conversion of WST-1 was determined as a measure of proliferation. Values (N ¼ 32) were
normalized in relation to control cells.
VEGF-A165 VEGF-A121 PlGF-1 PlGF-2 bFGF Aﬂibercept iBREC proliferation
[Mean þ SD]
Comparison GF(s)
to control
Comparison GF(s) to GF(s)
with aﬂibercept
e e e e e X 1.00  0.16
X e e e e e 1.15  0.19 p ¼ 0.001
X e e e e X 0.97  0.18 p ¼ 0.0009
e e X e e e 1.14  0.21 p ¼ 0.001
e e X e e X 0.97  0.12 p ¼ 0.0003
X X X X e e 1.14  0.20 p ¼ 0.001
X X X X e X 1.00  0.20 p ¼ 0.02
e e e e X e 1.33  0.18 p ¼ 0.0003
e e e e X X 1.35  0.27 p ¼ 0.0003 p > 0.05
GF: Growth factor.
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the formulation. Therefore, Eylea was used in these studies as an
aﬂibercept source, and similar to other VEGF-binding proteins
ranibizumab or bevacizumab, it did not alter basal proliferation of
iBREC (Table 1; Deissler et al., 2008, 2012). As supposed in view of
its binding proﬁle, 250 mg/ml aﬂibercept (Eylea) completely
inhibited iBREC proliferation induced by VEGF-A165, PlGF-1 and a
combination of VEGF-A165, VEGF-A121, PlGF-1 and PlGF-2 (each at
10 ng/ml) (Table 1). In contrast, aﬂibercept (Eylea) did not block
iBREC proliferation stimulated by bFGF (Table 1). Therefore, aﬂi-
bercept like other VEGF-binding proteins ranibizumab and bev-
acizumab speciﬁcally blocks VEGF-stimulated iBREC proliferation
at therapeutically achievable concentrations without changing
basal proliferation rates.3.3. Basal and VEGF-induced migration is inhibited by aﬂibercept
We previously reported that 25 ng/ml VEGF-A165 but not
VEGF-A121 or PlGF-1/-2 enhanced iBREC migration towards ﬁbro-
nectin and that 60 mg/ml ranibizumab (w1.2 mM) completely
inhibited this effect even in the presence of other growth factors
without inﬂuencing basal migration (Deissler et al., 2008, 2013a). In
contrast, basal migration of iBREC was blocked by aﬂibercept (Eylea
or Zaltrap) when applied at a therapeutically achievable concen-
tration of 150 mg/ml (w1.2 mM), but not in experiments with lower
amounts (Fig. 1A). Because the VEGF-A binding antibody bev-
acizumab also affected non-stimulated iBREC migration at this
concentration (Deissler et al., 2012), we studiedwhether an isotype-
matched control IgG similarly interferes with basal migration. The
humanized, chimeric MAb rituximab binds to B-cell-speciﬁc CD20
(Reff et al., 1994) but does not recognize any protein extracted from
iBREC (data not shown). Like aﬂibercept and bevacizumab, ritux-
imab contains a glycosylated IgG domain and is produced as a re-
combinant protein in Chinese hamster ovary cells. This unrelated
control antibody also inhibited basal iBREC migration (Fig. 1B)
although less efﬁciently than aﬂibercept or bevacizumab.
Migration stimulated by VEGF-A165 was also strongly inhibited
by therapeutically achievable 150 mg/ml aﬂibercept (Fig. 1C) as well
as migration caused by combined action of VEGF-A165, VEGF-A121,
PlGF-1 and PlGF-2 (each at 25 ng/ml; normalized values were
100  44% for control, 137  39% for growth factors and 38 þ 32%
for growth factors þ aﬂibercept, p  0.0007 for all comparisons). In
both cases, inhibition of stimulated migration resulted in values
even below basal migration rates. This overcompensation was also
observed in experiments with bevacizumab but not with ranibi-
zumab (Deissler et al., 2012). In addition, 150 mg/ml rituximab also
blocked VEGF-induced migration. However, when lower amounts
of aﬂibercept or rituximab were applied, VEGF-stimulatedmigrationwas only blocked by VEGF-binding aﬂibercept to baseline
migration but not by rituximab (Fig. 1C). Thus, aﬂibercept at a
therapeutically achievable concentration of 150 mg/ml suppresses
growth factor-independent basal as well as VEGF-induced iBREC
migration, but at lower concentrations only VEGF-stimulated iBREC
migration is affected.
3.4. Aﬂibercept slows down repair of lesions in iBREC monolayers
Because lesion repair involves both migration and proliferation
of the cells at the border, we investigated whether aﬂibercept or
rituximab also inhibit closure of experimentally interrupted cell
monolayers. After setting a lesion of 2 mm width, its repair was
monitored with or without 250 mg/ml aﬂibercept (Eylea) or ritux-
imab (Fig. 1D). Both antibody constructs weakly but signiﬁcantly
inhibited lesion repair.
3.5. Aﬂibercept efﬁciently restores a VEGF-A165-impaired iBREC
barrier
The barrier function of iBREC was assessed by measuring the
TER of conﬂuent cells and by Western blot-monitoring of the TJ-
protein claudin-1 because its presence strongly correlates with a
functional barrier (Deissler et al., 2008, 2011, 2013b). Compared to
the quantiﬁcation of the ﬂux of labeledmacromolecules of different
sizes through a monolayer of REC (Cai et al., 2011; Harhaj et al.,
2006) as a more direct approach to evaluate barrier function,
measuring TER is non-invasive and has the distinct advantage that
the same culture can be monitored easily during long-term ex-
periments by multiple subsequent measurements. Flux measure-
ments would have required repetitive addition of dye-labeled
macromolecules associated with more frequent exchanges of the
culture medium which might have undesirably disturbed the
cultivated cells in our experiments over several days. Extended
treatment of iBREC over 6 d with 250 mg/ml (w2 mM) aﬂibercept e
provided as Eylea or Zaltrap e did not result in signiﬁcantly
changed TER (Fig. 2A). Accordingly, expression of several TJ-
proteins and the adherens junction protein VECad was not altered
after treatment for 3 d (Fig. 2B).
Barrier disruption induced by100ng/mlVEGF-A165 is completely
restored by treatment with therapeutically achievable 100 mg/ml
ranibizumab or 250 mg/ml bevacizumab (Deissler et al., 2012). To
investigate whether exposure to aﬂibercept also results in normal-
ization of a VEGF-disturbed barrier, iBRECwere treated for 30 hwith
100 ng/ml VEGF-A165 before 100 mg/ml ranibizumab, 250 mg/ml
aﬂibercept, bevacizumab or the unrelated MAb rituximab were
added for additional 24h. Then expression of claudin-1, indicative of
a functional barrier, was measured. All tested VEGF-A-binding
Fig. 1. Basal and VEGF-A165-stimulated migration of iBREC is strongly inhibited by high amounts of aﬂibercept. (A)e(C) iBREC migration towards ﬁbronectin within 20 h was
measured in a modiﬁed Boyden-chamber (N  12 for each combination). (A) Only at a high concentration of 150 mg/ml aﬂibercept strongly inhibited basal migration. (B) Basal iBREC
migration was also inhibited by the CD20 binding humanized MAb rituximab. (C) Migration stimulated by treatment with 25 ng/ml VEGF-A165 was suppressed by 150 mg/ml
aﬂibercept clearly below the level of basal migration. At lower concentrations (15 mg/ml), aﬂibercept but not rituximab blocked VEGF-induced migration to basal level. (D) Cells
were scraped off a conﬂuent iBREC monolayer to create a gap which was closed by proliferating and migrating cells in about 2 d. Lesion repair was signiﬁcantly (p < 0.05 for values
at 6 h, 24 h, 27 h, 30 h) inhibited in the presence of 250 mg/ml aﬂibercept or rituximab (N  48 for each combination).
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restored claudin-1 whereas the chimeric antibody rituximab, used
as a control to conﬁrm speciﬁcity, did not (Fig. 3A). Both aﬂibercept
formulations, Zaltrap and Eylea, showed similar activity (data notFig. 2. TER and expression of TJ-protein in iBREC was not altered by aﬂibercept. Conﬂuent iB
incubation did not signiﬁcantly change in the presence of aﬂibercept compared to control
adherens junction protein VECad were constantly expressed by iBREC during treatment for
ml) as conﬁrmed by Western blot analyses.shown). To compare the efﬁcacies of aﬂibercept and ranibizumab,
iBREC were treated for 30 h with 100 ng/ml VEGF-A165 (w2.5 nM)
before the VEGF inhibitors were added at concentrations in the
range 0.01e10 mg/ml ranibizumab or 0.025e25 mg/ml aﬂiberceptREC were treated with 250 mg/ml aﬂibercept for several days. (A) TER measured during
cells (N ¼ 5 for each combination). (B) TJ-proteins claudin-1, claudin-5 and ZO-1, and
3 days with rituximab and VEGF binding aﬂibercept and bevacizumab (each at 250 mg/
Fig. 3. Aﬂibercept efﬁciently normalized the VEGF-A165-decreased levels of claudin-1 and TER. Conﬂuent iBREC were treated with 100 ng/ml VEGF-A165 (w2.5 nM) for 30 h before
VEGF binding proteins were added. (A) iBREC pre-treated with VEGF-A165 were exposed to 100 mg/ml ranibizumab or 250 mg/ml aﬂibercept, bevacizumab or rituximab (w2 mM) for
additional 24 h. Then expression of claudin-1 and claudin-5 was analyzed by Western blot. Only the VEGF binding proteins (not rituximab) completely restored lost claudin-1. (B)
iBREC were treated as described in (A) but 0.01e10 mg/ml ranibizumab or 0.025e25 mg/ml aﬂibercept (w0.2e200 nM) were added before expression of claudin-1 or claudin-5 was
analyzed 24 h later. To re-instate lost claudin-1 completely, 0.25 mg/ml aﬂibercept but 1 mg/ml ranibizumab were needed. (C) and (D) Cells were treated as described above and TER
was measured (C) 24 h after addition of aﬂibercept or (D) at indicated time points after addition of 100 ng/ml VEGF-A165. (C) Complete reversion of the TER decrease induced by
VEGF-A165 was achieved after treatment for 1 d with clinically relevant 250 mg/ml (w2 mM) aﬂibercept (N ¼ 5 for each combination). (D) Even low amounts of 25 mg/ml aﬂibercept
or 10 mg/ml ranibizumab (w200 nM) were sufﬁcient to completely restore a normal barrier function (N ¼ 5 for each combination).
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concentrations 0.25 mg/ml (w2 nM) which is nearly equimolar to
the amount of VEGF-A165 used in this experiment, lost claudin-1
completely reappeared, whereas 1 mg/ml (w20 nM) ranibizumab
were needed to achieve a similar effect.
That treatment with aﬂibercept or ranibizumab results in
normalization of a VEGF-affected iBREC barrier was conﬁrmed by
TER measurements: iBREC were incubated with 100 ng/ml VEGF-
A165 for 2 d before therapeutically achievable 250 mg/ml aﬂibercept
were added and TER was measured 24 h later. Complete reversion
of VEGF-A-induced TER reduction was observed (Fig. 3C). Under
these conditions, a strong claudin-1 band was detected by
Western-blot analysis (Fig. 3A). We also investigated the ability of
both VEGF-inhibitors used at lower concentrations to normalize a
VEGF-A induced barrier dysfunction: After incubation of iBREC
with 100 ng/ml VEGF-A165 (w2.5 nM) for 30 h, 25 mg/ml aﬂibercept
or 10 mg/ml ranibizumab (w200 nM) was added. VEGF-A-induced
reduction of TER was completely reverted by both VEGF-A bind-
ing proteins with very similar efﬁciency (Fig. 3D). Strong expression
of claudin-1 was observed under these conditions and the amount
was not dependent on the VEGF-inhibitor used (Fig. 3B).
3.6. Aﬂibercept is internalized by iBREC
We have recently shown that iBREC internalize bevacizumab
and ranibizumab which can be detected with polyclonal antibodiesdirected against human IgG (Deissler et al., 2012). Aﬂibercept and
rituximab also contain IgG domains and are recognized by these
antibodies with detection limits (25 ng for immunoﬂuorescence
staining, 0.5 ng for Western blot analyses) that are similar to those
of bevacizumab and ranibizumab (Deissler et al., 2012). To monitor
uptake by iBREC, their conﬂuent monolayers were incubated with
aﬂibercept for various periods from several hours to 6 days before
the cells were thoroughly washed and aﬂibercept was determined
in their lysates (Fig. 4A). Aﬂibercept e applied as Zaltrap or Eylea e
was detected after treatment for 1 h and the amount of internalized
protein slightly increased during prolonged incubation for up to 6 d
in medium containing aﬂibercept. However, when iBREC were
exposed for 1 d and then kept in medium without aﬂibercept for
additional 5 d, the recombinant proteinwas no longer detectable in
cell extracts (Fig. 4A). Pre-treatment of iBREC with 100 ng/ml
VEGF-A165 for 30 h did not affect uptake of aﬂibercept (Fig. 4B), as it
had not affected internalization of bevacizumab or ranibizumab
(Deissler et al., 2012). Similar uptake of rituximab by iBREC, which
does not recognize VEGF-A, was also observed (Fig. 4C).
3.7. Internalized aﬂibercept accumulates close to the Golgi
apparatus
To narrow down their intracellular localization, subcellular
fractions of iBREC treated with 250 mg/ml aﬂibercept, bevacizumab
or rituximab for 1e3 d were prepared and analyzed. Most of the
Fig. 4. Semi-quantitative assessment of aﬂibercept and rituximab taken up by iBREC. (A) iBREC were treated for 1 h to 6 d with 250 mg/ml aﬂibercept and whole cell extracts of
105 cells were subjected to Western blot analyses. Deﬁned amounts of aﬂibercept were also loaded for semi-quantitative assessment. A very strong aﬂibercept-speciﬁc band was
detected in the lane with the extract from cells treated only shortly for 1 h, and this signal was similarly intense when lysates from longer exposed cells were analyzed. As shown in
the right region of part A, internalized aﬂibercept had disappeared within 5 d of cultivation in medium not supplemented with this protein. (B) Conﬂuent iBREC were treated with
100 ng/ml VEGF-A165 for 30 h, before VEGF-binding proteins aﬂibercept, ranibizumab or bevacizumab were added. Treatment with aﬂibercept and bevacizumab resulted in strong
speciﬁc bands, but only a weak speciﬁc signal was seen in the lane with the extract from ranibizumab-exposed cells. (C) iBREC were treated for 1 h to 1 d with 250 mg/ml rituximab
and whole cell extracts of 105 cells were subjected to Western blot analyses. Deﬁned amounts of rituximab were loaded to allow semi-quantitative assessment. Two strong bands
speciﬁc for rituximab showed that substantial amounts of this antibody had been taken up after treatment for 1 h and that rituximab further accumulated during prolonged
exposure.
H.L. Deissler et al. / Experimental Eye Research 122 (2014) 20e31 27aﬂibercept absorbed by iBREC was found in the fraction consisting
of membranes and organelles and a small part associated with the
cytoskeleton (Fig. 5A). This subcellular localization was observed in
all experiments, independent of the time of exposure and addi-
tional treatment with VEGF-A165 (Fig. 5A, B). Whereas most aﬂi-
bercept and rituximab are found in the membrane and organelle
fraction, similar amounts of bevacizumab were in this fraction and
accompanying the cytoskeletal proteins (Fig. 5A).
Human IgG-speciﬁc immunoﬂuorescence staining of iBREC
treated with aﬂibercept showed its accumulation close to the nu-
cleus (Fig. 6A). This signal was strong after incubation for 3 h up to
2 d but decreased during prolonged exposure to aﬂibercept. Asso-
ciation of aﬂibercept with the plasmamembrane was not observed.
The intracellular distributions of aﬂibercept and rituximab were
similar but quite different from that of bevacizumab which was
visualized as a diffuse intracellular staining. To further characterize
intracellular aﬂibercept’s environment, co-immunoﬂuorescence
staining with antibodies directed against various organelle
marker proteins was performed (Fig. 6B). Co-localization of aﬂi-
bercept was not observed with CD63 (a marker of late endosomes;Kobayashi et al., 2000), with apoptosis inducing factor (AIF) local-
ized in mitochondria (Daugas et al., 2000), or with protein disulﬁde
isomerase (PDI), a marker for the endoplasmatic reticulum (Ellgard
and Ruddock, 2005). The only immunoﬂuorescence signals over-
lapping with staining of aﬂibercept were speciﬁc for proteins
(golgin 97 and the 58k-9 antigen (Gao and Sztul, 1999)) associated
with the Golgi apparatus.
4. Discussion
The recombinant protein aﬂibercept, which binds to VEGF-A,
VEGF-B and PlGF, has recently been added to the pharmaco-
therapeutical options in the treatment of DME (Do et al., 2012). In
almost all in vitro experiments performed to better understand the
mechanisms underlying aﬂibercept’s therapeutic effects, non-
retinal EC have been used (Yu et al., 2011; Papadopoulos et al.,
2012) although only microvascular retinal EC and their responses
to the different VEGF family members are considered to play an
important role in the development and progression of DR and DME.
We used the well established and characterized cell line iBREC to
Fig. 5. Different localization of aﬂibercept and bevacizumab in iBREC. iBREC were treated with 250 mg/ml aﬂibercept, bevacizumab or rituximab, and subcellular fractions of
2  104 cells were prepared and analyzed. (A) After treatment for 3 d, most of the aﬂibercept or rituximab were detected in the membrane/organelle fraction. In contrast, bev-
acizumab was also found in the fraction containing cytoskeleton proteins. (B) iBREC were treated with aﬂibercept in the absence or presence of 100 ng/ml VEGF-A165 for 1 d. Similar
distribution over the subcellular fractions indicated that localization of internalized aﬂibercept was not affected by treatment with VEGF-A165.
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proliferation, migration and cellular barrier by VEGF-A and PlGF
and to normalize the behavior of by then growth factor-disturbed
cells. Binding of VEGF by aﬂibercept, ranibizumab or bevacizumab
blocks its interaction with the corresponding receptors, thereby
preventing the initiation of a signal transduction cascade. Aﬂi-
bercept e like ranibizumab or bevacizumab e completely restored
a VEGF-A-induced dysfunction of the iBREC barrier indicated by
complete reappearance of lost TJ protein claudin-1. This was ach-
ieved even with lower concentrations of aﬂibercept compared toFig. 6. Visualization of internalized aﬂibercept in iBREC. (A) Aﬂibercept or bevacizumab w
ﬂuorescence staining with IgG-speciﬁc antibodies coupled to AlexaFluor 594 (red). Incubat
region close to the nucleus whereas a strong, diffuse intracellular staining was observed for b
of the cells for 1 d. In addition, organelle-speciﬁc proteins were stained green with spec
localization of aﬂibercept and 58K-9 Golgi is evident (yellow arrows) whereas overlappingranibizumab: in the presence of equimolar amounts of VEGF-A165
and the VEGF-binding proteins, aﬂibercept but not ranibizumab
still completely reverted VEGF-A165 induced loss of claudin-1 and
this is probably due to aﬂibercept’s higher afﬁnity to bind VEGF-A
(Papadopoulos et al., 2012). However, VEGF-A-reduced TER was
normalizedwith similar efﬁciencies by ranibizumab and aﬂibercept
when both were applied at concentrations well below the thera-
peutically achievable values. This is achieved by speciﬁcally binding
to extracellular VEGF-A: When used at clinically relevant concen-
trations, aﬂibercept, ranibizumab or bevacizumab completelyere visualized in iBREC treated with 250 mg/ml of one of these inhibitors by immuno-
ion with aﬂibercept for 3 h to 1 d or 2 d resulted in a strong intracellular staining of a
evacizumab. (B) Aﬂibercept was visualized in iBREC as described in (A) after treatment
iﬁc antibodies and appropriate secondary antibodies coupled to AlexaFluor 488. Co-
signals with other organelle marker proteins were not seen.
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body rituximab was not effective (data not shown). Recently we
have shown that aﬂibercept and ranibizumab are also similarly
efﬁcient in restoring barrier function of iBREC after extended
treatment with complex growth factor mixes containing VEGF-A
and PlGF (Deissler et al., 2013b). It can be concluded from these
observations, that at least concerning barrier normalization, addi-
tional binding of PlGF by aﬂibercept does not result in superior
efﬁcacy. This is not surprising because permeability of (i)BREC is
not affected by PlGF alone (Cai et al., 2011; Deissler et al., 2013b).
Similar to other VEGF binding proteins, aﬂibercept did not disturb
the iBREC barrier in the absence of VEGF-A (Deissler et al., 2012):
TER as well as expressed amounts of different TJ proteins were not
altered even during extended incubation with aﬂibercept.
Aﬂibercept like ranibizumab or bevacizumab, did not inﬂuence
basal proliferation of iBREC, but speciﬁcally and completely pre-
vented their VEGF-A165-stimulated proliferation which is in accor-
dance with studies performed with primary BREC (Yu et al., 2011).
Stimulation of proliferation by PlGF or by combined actions of
VEGF-A and PlGF was also completely inhibited by aﬂibercept. In
contrast, VEGF-A binding ranibizumab only partly prevented pro-
liferation induced under such conditions, suggesting parallel acti-
vation of independent signaling pathways by the different growth
factors (Deissler et al., 2013a). Additional binding of PlGF by aﬂi-
bercept, therefore, results in superior inhibition of at least one
process crucially involved in neovascularization.
Migration of (i)BREC is stimulated by VEGF-A165, but not by
VEGF-A121 or isoforms of PlGF. Depletion of VEGF-A with ranibi-
zumab is therefore sufﬁcient to prevent completely iBREC migra-
tion induced by these factors in vitro (Castellon et al., 2002; Deissler
et al., 2008, 2013a). When applied at lower concentrations, aﬂi-
bercept speciﬁcally blocked iBREC migration stimulated by
VEGF-A165 without affecting baseline migration. However, at clin-
ical relevant concentrations (150 mg/ml or w1.2 mM) both
VEGF-binding proteins aﬂibercept and bevacizumab as well as the
control antibody rituximab also strongly suppressed non-
stimulated iBREC migration (Deissler et al., 2012). The assumption
that this particular effect is independent of VEGF-A inactivation, is
supported by our ﬁndings that 1.2 mMVEGF-A binding ranibizumab
as well as speciﬁc inhibitors of VEGF receptors 1 and 2 did not affect
basal migration (Deissler et al., 2008, 2013). That basal migration
does not require VEGF-A can also be concluded from the fact that
substantial amounts of this factor, above the detection limits of
Western-blot analyses or enzyme-linked immunosorbent assays,
are not expressed and secreted by non-stimulated iBREC (Deissler
et al., 2011; data not shown). That even non-stimulated lesion
repair which involves proliferation as well as migration of the cells,
was slowed down in the presence of aﬂibercept or rituximab
emphasized their strong effect on migration. However, high
amounts (150 mg/ml which still can be achieved in vivo by intra-
vitreal injection) of aﬂibercept, bevacizumab or rituximab were
necessary to affect basal migration of iBREC migration or lesion
repair, indicating that this effect is not speciﬁc. A high number of
protein molecules per se seem not to be sufﬁcient because ranibi-
zumab at a similar molar concentration did not inhibit basal
migration of iBREC (Deissler et al., 2012, 2013a). A common feature
of the three proteins aﬂibercept, bevacizumab or rituximab is the
non-variable IgG domain suggesting that this unspeciﬁc effect is
most likely caused by high amounts of this domain. Cell migration
is a highly organized process involving several steps: extending the
leading edge of the cell, formation of new adhesions, translocation
of the cell body and detachment of the trailing edge of the cell (Kuo,
2013). Internalized VEGF-binding proteins aﬂibercept and bev-
acizumab as well as the control antibody rituximab were indeed
detected in different compartments of iBREC which are involved inthe migration process, i.e. plasma membrane/organelles and cyto-
skeleton (Fig. 5). Therefore, binding to a surface protein of iBREC e
either speciﬁc or unspeciﬁcemight prevent proper adhesion of the
migrating cell. Inhibiting translocation of the cell body by interac-
tion with cytoskeletal proteins actin or myosin could also be
involved. Further analysis is required to enlighten this aspect of
potential side effects of high intraocular concentrations of aﬂi-
bercept or bevacizumab.
Incubation of iBREC with aﬂibercept for 1 d resulted in inter-
nalization of substantial amounts of the protein e about 70,000
molecules per cell e and further slow accumulation was observed
during extended exposure to aﬂibercept for up to 6 d. This is in
contrast to internalized ranibizumab of which constant or even
slowly decreasing amounts were observed after initial uptake
(Deissler et al., 2012). Most likely, unbalanced uptake and degra-
dation (or secretion) of the proteins containing constant IgG do-
mains result in increases of their intracellular amounts in iBREC.
Surprisingly, uptake and internalization of molecules like aﬂi-
bercept or bevacizumab by iBREC does not depend on their ability
to bind to speciﬁc ligand(s) but seems to be a more general process
allowing these cells to take up antibodies and antibody-like pro-
teins. Even the control antibody rituximab which does not recog-
nize any protein expressed by iBREC, was internalized in a similar
manner suggesting also that the non-variable IgG domains of the
proteins mediate transition through the plasma membrane. One
might speculate that interaction with of Fc receptor(s) could play a
role: Binding of human IgG to the bovine neonatal Fc receptor
(FcRn) has been shown and different rodent ocular tissues
including retinal blood vessels express FcRn (Kacskovics et al.,
2006; Kim et al., 2008).
It has been reported that, in contrast to ﬁbroblasts and other cell
types, EC of non-retinal origin also can absorb antibodies: HUVEC
not only internalize MAb speciﬁc for antigens expressed by these
cells, among these are CD63 (Kobayashi et al., 2000) and the
membrane-associated angiotensin-converting enzyme
(Muzykantov et al., 1996). After being taken up by HUVEC, normal
human IgGs are detected in microsomes close to the nucleus
(Ronda et al., 1997). Aﬂibercept-speciﬁc immunoﬂuorescence was
seen after treatment of iBREC for 2 days in a region close to the
Golgi apparatus. This suggests an association with the Golgi appa-
ratus or derived vesicles which is in accordance with aﬂibercept’s
occurrence in subcellular fractions containing proteins from
membranes and organelles. Localization of internalized antibodies
close to the Golgi apparatus may indicate that they undergo
degradation and recycling processes, as proposed for non-
endothelial cells (Coffey et al., 2004). The mechanism of internali-
zation of aﬂibercept or bevacizumab by iBREC is unclear. Bev-
acizumab has been shown to form high molecular weight
complexes on the surface of HUVEC in the presence of VEGF-A165
and heparin (Julien et al., 2013) but uptake of bevacizumab or
aﬂibercept by iBREC does not require VEGF-A165. Formation of
complexes consisting of IgG and the extracellular matrix protein
ﬁbronectin and/or heparin has been suggested to be involved in the
uptake of IgG by EC mediated by integrins (Fujii et al., 2003).
However, uptake of aﬂibercept by iBREC was not prevented when
cells were cultivated in serum-free medium in the absence of
ﬁbronectin (data not shown). In addition, co-localization of aﬂi-
bercept with CD29, which is a part of the ﬁbronectin receptor, was
also not observed in iBREC, evenwhen both heparin and ﬁbronectin
were components of the culture medium used. Involvement of
complexes containing aﬂibercept, integrins together with extra-
cellular matrix proteins in its uptake by iBREC is therefore rather
unlikely.
Impairment of the VEGF/VEGF receptor system is a promising
therapeutic option for treating DME or DR because members of the
H.L. Deissler et al. / Experimental Eye Research 122 (2014) 20e3130VEGF family initiate processes crucially involved in the pathogen-
esis of the disease, i.e. proliferation, migration and modulation of
permeability of REC. Compared to the VEGF-A only binding rani-
bizumab, additional binding of PlGF by aﬂibercept does not result in
more efﬁcient restoring of a VEGF-disrupted iBREC barrier, but it is
a superior inhibitor of iBREC proliferation stimulated by both
members of the VEGF family. Therefore, a stronger clinical response
to aﬂibercept concerning retinal neovascularization seems possible.
Whether uptake of aﬂibercept during long-term treatment results
in deposits of the therapeutic protein in vivowhich may be harmful
in REC through unspeciﬁc inhibition of migration or otherwise,
remains to be seen. Because high amounts of intracellular aﬂi-
bercept may inﬂuence vital functions of REC, therapeutic admin-
istration of lower but still efﬁcient doses of aﬂibercept might be
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